Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Impact · against what's priced in

Black Diamond Therapeutics sees a significant valuation catalyst following positive Phase 2 results for silevertinib in frontline NSCLC patients. The combination of superior progression-free survival and the prevention of de novo brain metastases creates a clear path toward pivotal trials and potential commercialization.

BDTX+0.80

No priced-in read yet